Boston Scientific Corp. BSX, -1.90% posted better-than-expected third-quarter earnings early Thursday and raised its full-year guidance. The medical technology company had net income of $505 million, or 34 cents a share, for the quarter, up from $174 million, or 12 cents a share, in the year-earlier period.
Adjusted per-share earnings came to 50 cents, ahead of the 48 cent FactSet consensus. Sales rose to $3.527 billion from $3.170 billion a year ago, also ahead of the $3.477 billion FactSet consensus. The company now expects full-year adjusted EPS of $1.99 to $2.02, while FactSet is expecting $2.00. It expects full-year sales to rise 11%. The stock has gained 8% in the year to date, while the S&P 500 SPX, -1.43% has gained 9%.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Penske Automotive’s stock slides premarket after profit miss amid ‘challenging’ used car marketCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Lire la suite »